Sickle Blow For Pfizer’s Rivipansel At Phase III RESETs Expectations

After a long wait, the top-line data for Pfizer’s RESET study of the investigational treatment for sickle cell disease disappoint. Shares in rivipansel’s originator GlycoMimetics halved on the news.

Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells — • Source: Shutterstock

Pfizer Inc.’s RESET Phase III study of the selectin antagonist rivipansel in sickle cell anemia (SCA) has failed to meet its primary and key secondary endpoints.

Pfizer gained the drug after a successful Phase II read-out through its 2011 deal with Gaithersburg, MD-based GlycoMimetics Inc. that was at the time valued at up to $340m

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.